AIM vs. NKGN, EVAX, APTO, PLUR, SRZN, PMCB, INAB, INKT, ACHL, and TARA
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include NKGen Biotech (NKGN), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Pluri (PLUR), Surrozen (SRZN), PharmaCyte Biotech (PMCB), IN8bio (INAB), MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), and Protara Therapeutics (TARA). These companies are all part of the "biological products, except diagnostic" industry.
NKGen Biotech (NYSE:NKGN) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NKGen Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
In the previous week, NKGen Biotech had 3 more articles in the media than AIM ImmunoTech. MarketBeat recorded 5 mentions for NKGen Biotech and 2 mentions for AIM ImmunoTech. AIM ImmunoTech's average media sentiment score of 0.33 beat NKGen Biotech's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.
NKGen Biotech has a net margin of 0.00% compared to NKGen Biotech's net margin of -14,337.62%. AIM ImmunoTech's return on equity of 0.00% beat NKGen Biotech's return on equity.
AIM ImmunoTech has higher revenue and earnings than NKGen Biotech.
AIM ImmunoTech received 56 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Summary
NKGen Biotech beats AIM ImmunoTech on 9 of the 12 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
